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a  b  s  t  r  a  c  t
Mini-extracorporeal  circulation  (MECC)  constitutes  a novel  miniaturized  cardiopulmonary  bypass  (CPB)
circuit, heparin-coated  and  primed  with  aprotinin.  Its  membrane  oxygenation  is  similar  to conventional
cardio-pulmonary  bypass  (CCPB),  but it is  a  completely  closed-volume  system  due  to  the  lack of  the
venous  reservoir  which  has been  removed.  In  a mini  circuit,  the  reservoir  is  the  patient  himself.  Conse-
quently,  air  entering  the  venous  cannula  is  avoided.  Nevertheless,  the  capabilities  of MECC  have  been
expanded  either  by the  inclusion  of a suction  device  that is only  activated  on  direct  contact  with  liquid
in  some  circuits  or by postoperative  autotransfusion  of  the  wrecked  erythrocytes  by  a separate  suctioninimal extracorporeal circulation
inimal invasive cardiac surgery
xtracorporeal circulation
ff-pump coronary artery bypass
device  with  a cell-saver.  Although  the  tubing  diameter  is  similar  between  the  two  systems,  the tubing
length  of the  MECC  is  around  half that of  the  CCPB,  resulting  in the  restriction  of priming  volume.  As
a  consequence,  a higher  hematocrit  thus  a  limited  need  for  perioperative  blood  transfusion  is  achieved
due  to less  hemodilution.  In addition,  the inﬂammatory  response  is  also diminished  as  a  result  of  less
artiﬁcial  surface  area  interacting  with  blood.  Finally,  a  lower  dose  of heparin  is required  prior  to  MECC
than  prior  to  CCPB.© 2014  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
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Since 1953, when cardiopulmonary bypass (CPB) was intro-
uced in medicine for the restoration of a large atrial septal defect
n an 18-year-old woman [1], the equipment and methods have sig-
iﬁcantly developed leading to the gold standard in perfusion, the
onventional cardio-pulmonary bypass (CCPB) [2]. CCPB enables
ot only low mortality rates and appears to be safe [3,4], but also
rovides a blood-free ﬁeld for cardiac operations [2].
However, CPB is accompanied by various complications exac-
rbating the postoperative morbidity [5], which is relatively high.
ore than a third of the patients experience undesired effects due
o coronary artery bypass grafting (CABG) [6]. CCPB can induce an
nﬂammatory response and activate the coagulation process [2,7],
hich in combination with organ dysfunction leads to arrhythmias,
eurological disorders, prolonged bleeding, or thromboembolism
8,9]. Hemodilution and transfusion of blood products reinforce the
etrimental effects of CCPB [10].
Although beating heart revascularization (off-pump coronary
rtery bypass, OPCAB) was a ﬁrst thought in order to avoid these
ffects, cerebrovascular complications and survival were not sig-
iﬁcantly improved [2]. Moreover, technical difﬁculties are an
dditional obstacle in reaching satisfactory graft patency [11],
et alone that not all “open-heart” procedures can be performed
off-pump” [2]. Within the past decade, many innovations led to
he introduction of mini bypass extracorporeal circuits for CPB [12].
The minimal extracorporeal circulation (MECC) restricts the
ystemic inﬂammatory response syndrome (SIRS) via limiting the
lood–air interface, decreasing the artiﬁcial tubing length [2] and
eing more biocompatible thanks to complete heparin coating
f the circuit [10,13]. Preservation of a higher hematocrit during
PB due to less hemodilution, decreased blood and blood prod-
cts transfusion, and limited postoperative blood loss are some
dditional advantages of MECC. The ﬁnal result is less end-organ
amage, including the myocardium and the lungs [14,15]. Thus,
ECC has been successfully applied in CABG as well as in some
ases of aortic valve replacement (AVR) [7,16–18].
hat is MECC?
Generally, MECC constitutes a novel miniaturized CPB circuit,
eparin-coated and primed with aprotinin [19]. Its membrane oxy-
enation is similar to that of CCPB, reaching 7 L/min, whereas its gas
xchange surface area is as large as 2.4 m2 [5]. According to Mulhol-
and et al. [20], 10–15 operations are enough to be safely performed
nd as many as 50 MECC procedures sufﬁce for optimal knowledge
o be gained.
MECC procedures have some signiﬁcant differences compared
ith CCPB. It is a completely closed-volume system due to the
ack of the venous reservoir which has been removed [2,5,7,19].
n a mini circuit, the reservoir is the patient himself, so venous
eturn indicates cardiac output [21]. Consequently, air entering
he venous cannula is to be avoided mandatorily [2]. Absence
f a blood–air interface in the reservoir due to lack of the latter
ecreases the contact of blood with artiﬁcial components [22],
lood is not available for direct reinfusion; thus, suction devices
re not included. Nevertheless, the capabilities of MECC have been
xpanded either by the inclusion of a suction device that is only
ctivated on direct contact with liquid in some circuits or by the
ostoperative autotransfusion of the wrecked erythrocytes by a
eparate suction device with a cell-saver [2]. Moreover, MECC
ircuit does not include the cardioplegia delivery system either [5].
Another determinant difference when the MECC and the CCPB
re compared is the circuit length [2,5]. Although the tubing diam-
ter is similar between the two systems, the tubing length ofrdiology 63 (2014) 391–396
the MECC (80 cm)  is around half that of the CCPB (150 cm)  [23],
resulting in the restriction of priming volume (450–900 ml  vs.
1400–2200 ml  relatively) [2,5,22,23]. As a consequence, a higher
hematocrit thus a limited need for perioperative blood transfu-
sion is achieved due to less hemodilution [2,5,19]. In addition, the
inﬂammatory response is also diminished as a result of a less arti-
ﬁcial surface area interacting with blood [2]. Finally, a lower dose
of heparin is required prior to MECC (150–200 IU/kg) than prior to
CCPB (300 IU/kg) [2].
Where is MECC applied?
Although the selection criteria for MECC surgery instead of CCPB
differ widely from center to center, high-risk patients tend to be
excluded from MECC, as it is principally performed in isolated
CABG cases [5]. Aortic valve replacement via MECC has also been
reported [10,23]. MECC has also been used in isolated cases of CABG
with AVR [23], redo surgery (n = 3) [22], atrial septal defect closure
[24], mitral procedures (n = 5) [22], and thoracoabdominal aortic
aneurysm repair [25].
Deleterious effects of CCPB
An SIRS, causing platelet degradation and cytokine produc-
tion affecting all organs, is the most detrimental effect that CCPB
can induce [6,7,26]. The blame for this inﬂammatory response is
in some measure put on the interaction between blood compo-
nents and the various artiﬁcial surfaces within the CCPB apparatus,
the blood–air interface, and the harm of shedding pericardial
blood [2,7]. Coagulation disorders resulting in increased postopera-
tive bleeding, arrhythmias, endothelial dysfunction with increased
capillary permeability, prolongation of ventilation support, neuro-
logical complications, and multi-organ failure are potential results
of CCPB-induced SIRS [7,26–28].
Moreover, patients after CCPB are prone to have signiﬁcantly
lower postoperative hemoglobin and hematocrit due to the large
priming volumes that this method requires [2]. This hemodilu-
tion potentially affects hemostasis, decreasing levels of coagulation
and ﬁbrinolytic proteins [15]. Additionally, the risk of long-term
morbidity and short-term mortality is increased by hemodilution
[29]. Increased blood transfusion is often required due to exces-
sive hemodilution [30] to provide adequate oxygen delivery to
the vital organs [2]. Mechanical damage to red blood cells by the
roller pumps can also be a reason why  transfusion is needed [31].
However, blood transfusion as well as homologous blood products,
apart from the hazard of transfusion-related diseases, appears to
both contribute to the increase of postoperative long-term mor-
bidity and mortality and worsen health-related quality of life [32].
The potential ﬁnal result of all the aforementioned is end-organ
dysfunction or failure and neurological dysfunction [15,31].
Clinical comparisons of MECC with CCPB
Mortality
According to current literature, early survival rates are not
signiﬁcantly altered by MECC compared with CCPB and OPCAB
[13,16,33–35]. CCPB is associated with 30-day mortality rates rang-
ing from 1.5% to 2%, whereas those of MECC range from 1.25% to
4% (p = ns) [5]. In a recent study, the overall 30-day mortality after
CABG with MECC being of the order of 2.3% (1.1–13%) was even
signiﬁcantly better than CCPB [36]. No signiﬁcant changes in intra-
operative or hospital mortality after MECC compared with CCPB
are observed either [22–24,37]. Moreover, according to a 236-case
study with additive euroscore ≥6, even in these high-risk patients,
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he hospital mortality accompanying MECC (4.8%) was  not signif-
cantly higher than that accompanying CCPB (3.4%) (p = 0.75) [38].
onsequently, use of MECC appears to be safe [5]. Left ventricle
jection fraction lower than 30%, emergent surgery, and high-dose
atecholamine therapy are reported as predictors for mortality [36].
orbidity
Generally, postoperative complication frequency associated
ith MECC is similar to that of CCPB, also making MECC a safe
ethod with promising results [2,5]. Several reports [7,39] showed
o differences in pain experience, postoperative mediastinal blood
oss, inotropic requirements, postoperative functional New York
eart Association class, postoperative intubation, intensive care
nit (ICU) stay, hospital stay, or time taken for full return to daily
ctivities or work.
However, there are some studies reporting a reduction in venti-
ation time [15,24,33] and in ICU stay [15,16,33,34] when MECC is
sed instead of CCPB. Lower inotropic requirements, as well as sig-
iﬁcantly lower morbidity concerning lower incidence of stroke,
ow cardiac output, and respiratory insufﬁciency have also been
bserved [15,16]. Moreover, van Boven et al. [40] reported that the
se of MECC instead of CCPB led to decreased levels of oxidative
tress following reperfusion after the removal of the aortic cross-
lamp, as well as reduced levels of CC16 – a marker of alveolar
amage. Atrial ﬁbrillation (AF) often promoted by cardiac opera-
ions due to CABG-induced inﬂammation happens in more than
0% of patients receiving CCPB [26–28,41]. Immer  et al. [33] and
talder et al. [24] demonstrated that MECC was associated with
ostoperative AF by an 11–11.6% incidence compared to 39–39.4%
oncerning CCPB relatively (p < 0.001), although Remadi et al. [23]
howed no signiﬁcant differences (34% vs. 28%, p = ns). Finally,
oivisto et al. [38] found higher combined adverse end-point rate
n CCPB patients than in MECC ones when studying 236 high-risk
atients (20.4% vs. 13.5%, p = 0.18).
lood complications and transfusion
Although hemodilution occurring in CPB due to the mixing of
he priming volume with the patient’s blood [42] is useful favor-
ng tissue perfusion, it triggers an increased interstitial edema
n vital organs, such as brain, lungs, and myocardium, when the
ematocrit drops below 23% [19]. Tissue ischemia and end-organ
ysfunction are also promoted by hemodilution and the subse-
uent decrease in oxygen supply [2,7]. As a whole, MECC appears
o be superior to CCPB with regard to blood transfusion require-
ents [15], requiring just a third of that needed in CCPB patients [5],
hanks to the lower priming volume [13,16,22,33,34] and the use of
arm blood cardioplegia [2,7]. In addition, fewer ischemia, coagu-
ation, and bleeding disorders accompany MECC than CCPB, due to
ewer leukocyte–platelet coaggregates, lower prothrombin break-
own fragment levels, and reduced serum thrombin/antithrombin
II complexes [2,43].
Indeed, intraoperative blood transfusion was observed in 6.0%
f MECC cases versus 12.8% of CCPB cases (p < 0.001) according to
emadi et al. [22]. Stalder et al. [24] showed a mean red cell trans-
usion of 0.27 units in MECC patients compared with 2.79 units in
CPB ones (p < 0.05). Similar results were proved by Immer’s study
33], where only 9.3% of MECC patients required blood transfu-
ion postoperatively, whereas it was necessary in 31.9% of CCPB
atients. Moreover, Aal et al. [15] noticed that mini-CPB compared
o CCPB was associated not only with signiﬁcantly reduced blood
nd blood products transfusion requirements (1.47 ± 1.13 units
f RBCs vs. 2.05 ± 1.19 units of RBCs, 2.5 ± 1.62 units of fresh
rozen plasma vs. 3.55 ± 2.58 units of fresh frozen plasma, and
.95 ± 2.95 units of platelets vs. 3.23 ± 2.85 units of platelets) butrdiology 63 (2014) 391–396 393
also with decreased postoperative bleeding (531.62 ± 220.1 ml  vs.
729 ± 294.9 ml  of postoperative drainage). MECC was  also accom-
panied by less hemodilution, platelet consumption, chest tube
output, postoperative blood loss, and blood transfusion than CCPB
in a 199-case study with the patients undergoing CABG reported
by Sakwa and associates [44]. Even when combined CABG and AVR
are performed, the miniaturized system is superior to the con-
ventional one with regard to postoperative hemoglobin and blood
transfusion requirements [7]. Finally, as far as high-risk patients
are concerned, Koivisto et al. [38] proved similar postoperative
bleeding and transfusion requirements between MECC and CCPB,
although 4.8% of CCPB patients underwent resternotomy because
of bleeding against only 1.1% of MECC patients (p = 0.26).
Post-bypass inﬂammatory response
CPB is an independent risk factor for postoperative organ dys-
function since it generates a noticeable systemic inﬂammatory
response in the early postoperative period, potentially result-
ing in hemodynamic instability, multiple organ dysfunction, and
various complications thus prolonging ICU and hospital stay
[5,22,39,45–47].
The interactions among air, blood, and artiﬁcial surfaces of CPB
are responsible for this inﬂammatory response to which the phys-
ical surgical trauma, ischemia, and reperfusion contribute [48–50].
Proinﬂammatory cytokines and complement activation trigger
this phenomenon [51], and mast cells, basophils, and primarily
neutrophils mediate it [28]. Either complement or heparin-
protamine activates neutrophils and the ischemia/reperfusion
injury stimulates the emission of cytokines such as interleukin (IL)-
1, IL-6, and IL-8 due to thrombin deposition [2,28]. Furthermore,
the retransfusion of pericardial shed blood, containing proinﬂam-
matory mediators and damaged red blood cells [31], stimulates an
inﬂammatory response and affects hemostasis [52,53].
During recent years, extracorporeal circuits have been coated
with more biocompatible materials. Among heparin [54–56],
poly-2-methoxyethyl acrylate [57], synthetic protein [58], and
phosphorylcholine [59] being used as coating components, the
most popular one is heparin [19]. The endothelial surface includes
heparin sulphate and that is why heparin coating is preferred [60].
The beneﬁts gained by heparin-coated circuits are a restriction of
complement activation (mainly of factor C5a) ranging between 25%
and 45% [61,62], and a decrease in the inﬂammatory response via
the limitation of complement activation and binding of phospholi-
pase A2 [63]. The ﬁnal result is improved clinical outcomes, thanks
to a decrease in the inﬂammatory response being considerable by
reduced levels of IL-6, IL-8, E-selectin, lactoferin, myeloperoxidase,
integrin, selectin, platelet b-thromboglobulin, and oxygen-free rad-
icals [19,63–66]. Nevertheless, heparin appears not to inﬂuence
thrombin production and ﬁbrinolysis [67].
MECC manages to restrict SIRS and its complications, thanks to
its shorter tubing length and more biocompatible coating decreas-
ing the interaction between blood and artiﬁcial components [5].
Additionally, the miniaturized circuits use a centrifugal pump caus-
ing less damage to the circulating red blood cells, thus contributing
to inﬂammation reduction [23]. Hence, the miniaturized circuit
improves early clinical outcomes [7].
C-reactive protein (CRP), leukocytes, and cytokines showing
inﬂammation are lower when MECC is used [2], although some
authors failed to detect any signiﬁcant difference between MECC
and CCPB patients [34,68]. According to Remadi et al. [22] in their
400-case study, CRP levels were signiﬁcantly lower in MECC cases
than in CCPB ones both at 24 and 48 h postoperatively. In Fromes’s
study [13] monocytes reduced more in the CCPB group than in the
MECC group due to greater dilution, and their level was  elevated
signiﬁcantly less in the MECC group (p = 0.002), proving a weaker
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nﬂammatory response. With regard to cytokines, it is not clear
hether IL-1 levels rise in cardiac operations [51,69,70]. No sig-
iﬁcant increase in IL-1 either in MECC or in CCPB was proved
y Fromes et al. [13]. Contrary to this, IL-6 levels rose signiﬁcantly
ess in MECC patients than in CCPB ones (p = 0.04). The increase
n tumor necrosis factor- was also smaller in MECC compared to
CPB (p = 0.002) [13]. Immer  et al. [33], in 60 patients undergoing
ABG, also showed signiﬁcantly lower postoperative levels of IL-6
nd SC5b-9 (a complement complex often raised in inﬂammation)
n the MECC group in comparison with the CCPB group. Moreover,
L-8 was also signiﬁcantly lower in MECC patients on the ﬁrst post-
perative day in Ohata’s study [68]. Finally, two studies [13,68],
omparing postoperative serum neutrophil elastase (a marker of
ctivated neutrophils) between patients treated with either CCPB
r MECC detected lower levels in the MECC cases.
yocardial protection
Various factors participate in the postoperative myocardial
njury. Ischemia and reperfusion injury due to aortic cross-
lamping as well as surgical trauma itself constitute some of these
actors. Furthermore, CPB circuits themselves appear to indepen-
ently cause damage to the myocardium [2,71]. According to
he literature, cardiac-speciﬁc enzymes, indicative of myocardial
njury, present lower levels after MECC compared to CCPB cases
10,22–25,72]. Indeed, Immer  et al. [33], in their 1257-patient
MECC: n = 931; CCPB: n = 326) study, observed signiﬁcantly lower
roponin I levels at 6, 12, and 24 h after CABG using MECC. Similar,
esults were also detected by Stalder et al. [24]. In a similar 60-case
tudy by Skrabal et al. [71], MECC was associated with signiﬁcantly
ower postoperative levels of troponin T and creatine kinase-MB
n the serum than CCPB. Furthermore, according to Beghi et al.
34] MECC was superior to CCPB in terms of cardiac output which
as increased in the former, and pulmonary vascular resistance
hich was decreased again in the former. Even as far as high-risk
atients are concerned, Koivisto et al. reported a stroke rate of the
rder of 5.4% among CCPB patients against 0% among MECC patients
p = 0.026) [38]. Hence, there is a superiority of MECC to CCPB with
egard to myocardial protection after cardiac surgery [2].
eurological dysfunction
Reversible or irreversible neurological dysfunction also consti-
utes a considerable complication of CPB because of air, calcium,
nd debris from the surgical ﬁeld entering the arterial circulation
5]. According to Lilly et al. [73], the incidence of imperceptible
ysfunction is 79%. Postoperatively, patients can experience many
ymptoms ranging from disorientation to focal neurological disor-
ers and psychiatric symptoms [5]. Although Stalder et al. [24] did
ot report signiﬁcant differences among MECC and CCPB in terms
f strokes, Remadi et al. [22] showed signiﬁcantly decreased neu-
ological complications associated with MECC compared to CCPB
n their 400-case study (1 vs. 7, p = <0.01).
dverse MECC-related events
Despite its inferiority, CCPB use permits the immediate deal of
ir entering venous lines [7]. Nevertheless, similar quantities of air
n the MECC circuit, entering the venous line through suture holes
t the venous cannulation point [15], are able to stop the function
f the pump or induce embolization [22]. In order to prevent signif-
cant air introduction to the circulation, it is mandatory to assure
he absence of an atrial septal defect (ASD) [21].
Air embolization appears to be the predominant cause of neu-
ological disorders in cardiac operations, so MECC makes de-airing
ndispensable in order to prevent them [7]. That is the reason why
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an extra purse-string around the venous cannula can be used [2].
Other techniques for successful de-airing include continuous CO2
ﬁeld bombarding, patient’s Trendelenburg position, cessation of the
pulmonary artery vent, renewing ventilation to vent out air from
the pulmonary circulation, and suction to the aortic root vent before
unclamping the aorta [7].
Conclusion
MECC circuits, despite their accompanying risks, provide a
safe procedure to perform CABG, decreasing the postoperative
CPB-associated morbidity thanks to the restriction of SIRS, with
potential improvement in clinical outcomes [5]. The endothelial
damage, the granulocyte sequestration, and its activation are much
lower since the artiﬁcial surface is smaller [74,75]. Furthermore,
a miniaturized circuit leads to less hemodilution and less blood
loss than conventional CPB and as a result, less blood and blood
products requirements [15,21]. Hence, end-organs are better pro-
tected and low mortality rates are achieved when MECC is used
[36,76]. Therapeutic advantages of less invasive procedures have
been studied by Akagi [77], while Osaka et al. [78] investigated for
myocardial protection the human atrial natriuretic peptide (hANP)
during cardiac surgery. In conclusion, although MECC constitutes
a promising alternative to CCPB preventing the drawbacks of the
latter [2], it is not the ﬁnal step of bypass technology since it still
triggers inﬂammation [5].
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